Core Viewpoint - Takeda has entered into a license and collaboration agreement with Innovent Biologics for the development, manufacturing, and commercialization of two late-stage oncology medicines, IBI363 and IBI343, outside of Greater China [1] Group 1: Agreement Details - The collaboration focuses on two oncology medicines: IBI363 and IBI343 [1] - IBI363 is being evaluated for non-small cell lung and colorectal cancers, with potential efficacy in additional solid tumor types [1] - IBI343 is also part of the collaboration, although specific details on its indications were not provided [1]